Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

2004 ◽  
Vol 40 (3) ◽  
pp. 383-389 ◽  
Author(s):  
T. Robak ◽  
J.Z. Blonski ◽  
J. Gora-Tybor ◽  
M. Kasznicki ◽  
L. Konopka ◽  
...  
2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Teng Fong Ng ◽  
Benedict Carnley ◽  
Celia Green ◽  
Dominic Spagnolo ◽  
Michael F. Leahy

Chronic lymphocytic leukaemia is a slow-growing leukaemia of developing B-lymphocytes, which may transform to an aggressive lymphoma known as Richter’s syndrome. While Richter’s syndrome can present in untreated or relapsed-refractory cases, it may occur upon the commencement of less intensity treatment regimens. We present a case of Richter’s syndrome following treatment with chlorambucil and obinutuzumab and review of available literature on the topic.


1996 ◽  
Vol 92 (2) ◽  
pp. 375-381 ◽  
Author(s):  
Antonio Cuneo ◽  
Cristiano De Angeli ◽  
Maria Grazia Roberti ◽  
Nadia Piva ◽  
Renato Bigoni ◽  
...  

eJHaem ◽  
2021 ◽  
Author(s):  
Yandong Shen ◽  
Luke Coyle ◽  
Ian Kerridge ◽  
William Stevenson ◽  
Christopher Arthur ◽  
...  

2021 ◽  
Author(s):  
Yandong Shen ◽  
Luke Coyle ◽  
Ian Kerridge ◽  
William Stevenson ◽  
Christopher Arthur ◽  
...  

Chronic lymphocytic leukaemia (CLL) is invariably accompanied by some degree of immune failure. CLL patients have a high rate of second primary malignancy (SPM) compared to the general population. We comprehensively documented the incidence of all forms of SPM including skin cancer (SC), solid organ malignancy (SOM), second haematological malignancy (SHM), and separately Richter's Syndrome (RS) across all therapy eras. Among the 517 CLL/SLL patients, the overall incidence of SPMs with competing risks were SC 31.07%, SOM 25.99%, SHM 5.19% and RS 7.55%. Melanoma accounted for 30.3% of SC. Squamous cell carcinoma (SCC), including 8 metastatic SCCs, was 1.8 times more than basal cell carcinoma (BCC), a reversal of the typical BCC:SCC ratio. The most common SOM were prostate (6.4%) and breast (4.5%). SHM included 7 acute myeloid leukaemia and 5 myelodysplasia of which 8 were therapy-related. SPMs are a major health burden with 44.9% of CLL patients with at least one, and apart from SC, associated with significantly reduced overall survival. Dramatic improvements in CLL treatment and survival have occurred with immunochemotherapy and targeted therapies but mitigating SPM burden will be important to sustain further progress.  


Sign in / Sign up

Export Citation Format

Share Document